Research and Markets: The Worldwide Prescription Drug Market 2004; The Market Size for Worldwide Human Prescription Drugs at Year-End 2002 Was $430 Billion.

Business Editors

DUBLIN, Ireland--(BUSINESS WIRE)--April 27, 2004

Despite the current weak global economy the market is projected

to grow to about $543 billion in 2005 with a CAGR of about 8.1%

Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Worldwide Prescription Drug Market 2004 to their offering.

This report is about the worldwide market for human prescription drugs as it transitions through 2003. The study provides readers with recent information and analysis about key developments driving the industry. The research reviews the broad areas of major company activities ranging from planning new drugs with disease demographics, through to strategic alliances, and market forecasts. The report reviews the challenges of patent expirations, developing new drug pipelines and what companies must do to get their drugs approved around the world. A review of price/cost aspects and drug distribution approaches uncovers the kinds of business activities that the pharma companies must do the market their products through to the end patients in different countries.

The worldwide pharmaceutical industry is complex to all the business participants as well to the end patients. The report works from the standpoint of disease categories and unravels what the key health issues are through disease demographic data from around the globe. The study looks at what disease categories of the top 276 drug products that the drug companies are selling and ranks the best selling areas and products.

This study has found that the market size for worldwide human drugs at yearend 2002 was about $430 billion. Despite the current weak global economy, the market is projected to grow to about $543 billion in 2005 with a CAGR of about 8.1%. The pharmaceutical industry faces numerous challenges that could be helped with newer business approaches. The report discusses these important items with interesting and useful findings. This study uses more than 48 figures and tables to illustrate the findings. Detailed information about the activities of the top companies important to this market is listed in numerous areas of this report.

Major Disease and the Disease Breakdown

Cancer

Colorectal cancer, Breast cancer, Lung/airway cancers, Prostate cancer, Bladder cancer, Lymphomas, Multiple myeloma, Stomach cancer, Melanoma and other skin cancers, Uterine cancer, Pancreas cancer, Leukemia, Liver cancer, Ovarian cancer, Mouth and throat cancers, Esophagus cancer, Cervical cancer

Cardiovascular

Ischemic heart disease (angina heart attack), Cerebrovascular disease (stroke), Other cardiovascular diseases, Hypertensive heart disease (angina, CHD), Inflammatory heart disease (from Infection)

Central Nervous System (CNS)

Migraine, Depressive disorders, Alcohol use disorders, Alzheimer and other dementias, Insomnia (primary), Drug use disorders, Epilepsy, Bipolar disorder, Schizophrenia, Panic disorder, Obsessive-compulsive disorder, Post-traumatic stress disorder, Parkinson disease, Multiple sclerosis

Gastro-Intestinal

Misc. digestive diseases, GERD, etc, Peptic ulcer disease, Cirrhosis of the liver, Appendicitis

Infections

Tuberculosis, STDs excluding HIV, Chlamydia, Gonorrhea, Syphilis, HIV/AIDS, Diarrheal diseases, Childhood diseases, Pertussis, Measles, Tetanus, Poliomyelitis, Diphtheria, Meningitis, Streptococcus pneumoniae, Meningococcemia without, Hemophilus influenzae, Hepatitis B, Hepatitis C, Malaria, Lower respiratory infections including Influenza, pneumonia, or others

Metabolic

Diabetes

Musculo-skeletal

Osteoarthritis, Rheumatoid arthritis

Respiratory

Asthma, Chronic obstructive pulmonary disease 

Skin

Skin diseases

Urogenital

Benign prostatic hypertrophy, Renal failure

Report Contents:

1. Major Disease Populations in the Developed World

2. Regulatory Issues By Disease: Drug Development & Sales

3. Current Drug Patent Expiration Date and New Drug Pipeline in Development By

4. Price, Cost & Distribution Structure

5. Strategic Alliances and M&As By Disease

6. WW Rx Drug Market Size and Forecast by Disease

7. Top Selling Rx Drugs by Revenue and Pharmaceutical Companies

8. Conclusions and Thoughts

9. Appendix

List of Tables

List of Illustrations

For more information visit http://www.researchandmarkets.com/reports/c1573